Lonza Group AG (OTCMKTS:LZAGY – Get Free Report) was the recipient of a large decrease in short interest during the month of November. As of November 30th, there was short interest totalling 200 shares, a decrease of 98.9% from the November 15th total of 18,600 shares. Based on an average daily volume of 286,800 shares, the short-interest ratio is currently 0.0 days.
Wall Street Analyst Weigh In
Several research analysts have recently issued reports on the company. The Goldman Sachs Group raised Lonza Group to a “strong-buy” rating in a research note on Wednesday, October 9th. Redburn Atlantic upgraded shares of Lonza Group to a “strong-buy” rating in a research report on Wednesday, November 27th.
Read Our Latest Analysis on Lonza Group
Lonza Group Price Performance
About Lonza Group
Lonza Group AG, together with its subsidiaries, supplies various products and services for pharmaceutical, biotech, and nutrition markets in Europe, North and Central America, Latin America, Asia, Australia, New Zealand, and internationally. It operates through Biologics, Small Molecules, Cell & Gene, and Capsules & Health Ingredients segments.
Featured Articles
- Five stocks we like better than Lonza Group
- Ride Out The Recession With These Dividend Kings
- FinWise Bancorp’s CEO Talks Strategy Behind Fintech Success
- What is a Death Cross in Stocks?
- Broadcom: Turning the Mag 7 Into 8 Trillion-Dollar Tech Giants
- Best Stocks Under $10.00
- SoundHound AI: Can Its Meteoric Rise Sustain Into 2025?
Receive News & Ratings for Lonza Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lonza Group and related companies with MarketBeat.com's FREE daily email newsletter.